Allergies & Asthma

Omalizumab (Xolair) maintained efficacy for chronic rhinosinusitis with nasal polyps, a researcher reported. In an open-label extension study of two, 24-week clinical trials, omalizumab was associated with significant improvements in nasal polyp scores (mean change -0.97, 95% CI -1.25 to -0.69), nasal congestion scores (mean change -0.99, 95% CI -1.14 to -0.83), and Sino-Nasal Outcome
0 Comments
Owning a dog while pregnant appeared to shape children’s immune systems well into adolescence, a researcher reported. In a cohort of 1,193 mother-child pairs in southeast Michigan, the area under the curve for immunoglobulin E levels over ages 10-14 (“IgE trajectory”) was 28.8% lower in children with prenatal pet exposure vs children whose mothers kept
0 Comments
Treatment with the investigational anti-IgE biologic ligelizumab was generally effective in patients with H1 antihistamine-unresponsive chronic spontaneous urticaria (CSU) who did not achieve complete symptom control with omalizumab (Xolair), an exploratory analysis of a phase IIb extension study showed. In a subset of omalizumab-treated patients with a score greater than 0 on the 7-day urticaria
0 Comments
The investigational monoclonal antibody tezepelumab proved to be an effective therapy for uncontrolled severe asthma in patients with and without perennial and seasonal allergies, a post-hoc analysis of data from the phase II PATHWAY study found. The subgroup analysis focused on patients who did and did not have baseline sensitivity to perennial allergens such as
0 Comments
Results from a preliminary study showed novel voice and breath analysis using a smartphone app to be a useful measure of lung function, and researchers say the technique may prove to be a valuable tool for identifying and monitoring respiratory disease. Automated voice and breath analysis was found to have value for predicting lung function,
0 Comments
Patients with cancer and COVID-19 have a higher risk of severe disease and mortality, researchers reported. Of 89 cancer patients admitted to the intensive care unit (ICU) due to COVID-19, 32 died, a mortality rate of 36%, reported Michael Dang, MD, a critical care fellow at Memorial Sloan Kettering Cancer Center in New York City,
0 Comments
Patients diagnosed with chronic obstructive pulmonary disease (COPD) who reported using marijuana had less risk of in-hospital mortality and pneumonia than non-users, according to a nationwide population-based study. Use of marijuana was associated with a 37.6% reduction in the odds of dying in the hospital (OR 0.624, 95% CI 0.407-0.958, P=0.0309) among patients diagnosed with
0 Comments
There is no medical justification for exempting respiratory patients from compulsory face mask regulations, and doing so places this already vulnerable population at greater risk for COVID-19, a global group of pulmonary specialists said. Beginning in May, the Spanish government mandated face masks in open- and closed-space public places, but the mandate exempted people with
0 Comments
earn free cme credit Earn CME credit by reading this article and completing the posttest. Sign Up Study Authors: Cornelia A. Verberkt, Marieke H.J. van den Beuken-van Everdingen, et al.; Eric W. Widera Target Audience and Goal Statement: Pulmonologists, pain management specialists, primary care physicians, public health and policy experts The goal of this study
0 Comments
Fixed-dose triple therapy with fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) improved lung function in adults whose asthma was uncontrolled with an inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA), the CAPTAIN study showed. On Wednesday, based on findings from the trial, the FDA approved the chronic obstructive pulmonary disease treatment at two different doses for adults 18 and
0 Comments
Specific genetic alterations in children and teens with asthma may identify those who will not benefit from treatment with the long-acting β2-adrenergic receptor agonist (LABA) salmeterol, a researcher reported. For the study, 241 children and teens (age 12-18) with asthma taking inhaled corticosteroids were randomly assigned (1:1) to receive personalized care (prescribing by rs1042713 genotype)
0 Comments
Vitamin D3 supplementation added to low-dose inhaled corticosteroids was not associated with longer time to asthma exacerbations among high-risk children with low baseline 25-hydroxyvitamin D levels, researchers reported. The mean time to exacerbation was 240 days in children randomized to the vitamin D3 supplementation group and 253 days in the placebo group (mean group difference
0 Comments
Short-term treatment with a low-dose opioid was associated with significantly improved health status in chronic obstructive pulmonary disease (COPD) patients with advanced disease and chronic breathlessness despite optimal pharmaceutical and non-pharmaceutical treatment. In a randomized trial of over 100 patients, twice daily treatment for 4 weeks with an oral sustained-release morphine (10 mg) was associated
0 Comments
As another so-called triple therapy for chronic obstructive pulmonary disease (COPD) hits the market, pulmonologists and primary care physicians are beginning to consider which patients are most appropriate for these treatments, and how much added benefit these products offer relative to more conventional — and better understood — two-drug combinations. The FDA approved AstraZeneca’s fixed-dose,
0 Comments